Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • J&J axes eye disease gene therapy after key phase 2b readout

J&J axes eye disease gene therapy after key phase 2b readout

July 15, 2026Posted inBiotechnology

Johnson & Johnson has stopped development of an eye disease gene therapy after reviewing data from one of its key readouts for 2026.

Post navigation

Previous Post
optical-singularity-protractor-enables-rotating-metrology-with-neuromorphic-sensors Optical Singularity Protractor Enables Rotating Metrology with Neuromorphic Sensors
Next Post
Big Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metal

Recent Posts

  • Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant
  • Deep-learning CT reconstruction sharpens calcium visibility in phantom tests, but dose evens the score
  • One gene locus flags atrial fibrillation risk after major surgery, UK Biobank study finds
  • Serum and urine protein biomarkers may sharpen prostate cancer detection beyond PSA
  • Most Ethiopian HIV patients on dolutegravir therapy show good knowledge, survey finds

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top